ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,964.73
-0.35%
Dow Jones
43,822.40
-0.31%
US Dollar vs MXN
20.5082
-0.12%
Brent Oil
72.115
0.35%
Bitcoin
88,951.83
-1.78%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. TransMedics Group Inc (TMDX)

  7. TransMedics Group Inc (TMDX) Noticias

TransMedics Group Inc

TransMedics Group Inc (TMDX)

NASDAQ
90.61
-2.12
( -2.29% )
Actualizado: 11:07:58
Delayed by 15 minutes

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Premium

TMDX Noticias

Solo noticias oficiales

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
07 Noviembre 2024
TMDX (-2.29%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
05 Noviembre 2024
TMDX (-2.29%)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Edgar (US Regulatory)
29 Octubre 2024
TMDX (-2.29%)

Form 8-K - Current report
Edgar (US Regulatory)
28 Octubre 2024
TMDX (-2.29%)

Form 8-K - Current report
Edgar (US Regulatory)
11 Septiembre 2024
TMDX (-2.29%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
29 Agosto 2024
TMDX (-2.29%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
27 Agosto 2024
TMDX (-2.29%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
09 Agosto 2024
TMDX (-2.29%)

TMDX Discussion

Ver más
Monksdream Monksdream 6 meses hace
TMDX new 52+ week high
👍️0
Monksdream Monksdream 9 meses hace
TMDX 10Q
👍️0
make it happen make it happen 1 año hace
Should touch $50 net lose widens, and has a 40% day. The structure shows over 100% ownership which technically should be illegal. How can there be over 100%? Imho mean institutions and whomever will be selling for a 40%ish profit overnight.
👍️0
crudeoil24 crudeoil24 4 años hace
TransMedics Late Tuesday Announced FDA Advisory Committee Panel Voted 12 To 5 That Benefits Of OCS Heart System Outweigh Risks
6:58 am ET April 7, 2021 (Benzinga) Print
TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today that after the review of TransMedics' clinical evidence from the OCS Heart EXPAND trial, the associated Continued Access Protocol ("CAP") results, as well as the OCS Heart PROCEED II trial, the Circulatory Systems Device Advisory Panel convened by the U.S. Food and Drug Administration ("FDA") has issued a favorable vote in support of approval of the OCS Heart System to the FDA's Office of Health Technology 2 (Cardiovascular Devices). The panel voted 12 to 5, with 1 abstaining, that the benefits of the OCS Heart System outweigh its risks. The panel voted 10 to 6, with 2 abstaining, that there is reasonable assurance that the OCS Heart System is effective. The panel voted 9 to 7, with 2 abstaining, that there is reasonable assurance of the OCS Heart System's safety.

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
👍️0
crudeoil24 crudeoil24 4 años hace
Transmedics group, Inc. is a commercial-stage medical technology company. It is focused on developing organ transplant therapy for end-stage organ failure patients across multiple disease states. The Company has designed and developed organ care system (OCS) a portable organ perfusion, optimization and monitoring system that utilizes customized technology to replicate near-physiologic conditions for donor organs outside of the human body. It has developed three OCS products, one for each of lung, heart and liver transplantations. Its OCS clinical programs include OCS Lung INSPIRE Trial, OCS Lung Expand Trial, OCs Heart EXPAND and PROCEED II Trials. Its organ care system (OCS) technology platform to perfuse donor organs with warm, oxygenated, nutrient-enriched blood, while maintaining the organs in a living, functioning state; the lung is breathing, the heart is beating and the liver is producing bile. It is also focused on developing additional OCS products for kidney transplantation.
👍️0

Su Consulta Reciente

NASDAQ
TMDX
TransMedics
LSE
MLCO
Merrill Lynch Com
BIT
RARE
ETF
TG
RARE
WisdomTree Issuer ICAV
USOTC
ASHTY
Ashtead (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados